EnzAdapt: Feasibility, acceptability and safety of adaptive dosing of enzalutamide in men with metastatic castrate-resistant prostate cancer
Latest Information Update: 16 Sep 2020
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Acronyms EnzAdapt
Most Recent Events
- 15 Sep 2020 Status changed from not yet recruiting to recruiting.
- 15 Apr 2019 New trial record